Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer

Fineline Cube Apr 12, 2026
Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026
Company Deals

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Fineline Cube Apr 12, 2026
Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer

Fineline Cube Apr 12, 2026
Company Drug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Fineline Cube Apr 12, 2026
Company Deals

Bayer AG Leads Series D Investment in Jixing Pharmaceuticals, Eyeing Commercialization Rights

Fineline Cube Jan 8, 2024

Bayer AG (ETR: BAYN, OTCMKTS: BAYRY), a leading German pharmaceutical company, has announced a long-term...

Policy / Regulatory

China’s NMPA Issues Guidelines for Inspection of Third-Party Online Drug Trading Platforms

Fineline Cube Jan 8, 2024

The National Medical Products Administration (NMPA) has issued a new set of “Guidelines for the...

Company Deals

Novartis Strikes Deal with Argo Biopharma for Global Rights to siRNA Drug Candidates

Fineline Cube Jan 8, 2024

Argo Biopharma, a Shanghai-based developer of small interfering RNA (siRNA) drugs, has secured a licensing...

Company Deals

Novartis to Fully Acquire SanReno Therapeutics to Expand Kidney Drug Portfolio in China

Fineline Cube Jan 8, 2024

Novartis (NYSE: NVS), a Swiss pharmaceutical giant, has announced plans to acquire the remaining shares...

Company Drug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Nod for SGLT-2 Inhibitor and Metformin Combo for Type 2 Diabetes

Fineline Cube Jan 8, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...

Company Medical Device

MicroPort CardioFlow Medtech’s AnchorMan System Receives NMPA Approval as First Semi-Closed LAA Occluder in China

Fineline Cube Jan 8, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...

Company Deals

Ningbo Linstant Polymer Materials Secures Over USD 14 Million in Series B Financing to Boost Production and Global Reach

Fineline Cube Jan 8, 2024

Ningbo Linstant Polymer Materials Co., Ltd, a Chinese manufacturer specializing in polymer accessories for medical...

Company Deals

Lion TCR Partners with MaxCyte to Develop mRNA-Based TCR-T Therapies for Solid Tumors and Viral Diseases

Fineline Cube Jan 8, 2024

Lion TCR, a Singapore-based clinical-stage biotechnology company with backing from Chinese investors, has entered into...

Company Deals

OnCusp Therapeutics Secures Oversubscribed USD 100 Million Series A Financing for CDH6-Targeting ADC

Fineline Cube Jan 8, 2024

OnCusp Therapeutics, a U.S.-based biopharmaceutical company, has closed an oversubscribed Series A financing round, raising...

Company Deals

Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential

Fineline Cube Jan 5, 2024

Germany-based Merck (NYSE: MRK) has in-licensed the potential first-in-class candidate ompenaclid from U.S. firm Inspirna,...

Company Deals

Boehringer Ingelheim Teams Up with 3T Biosciences for Next-Gen T-Cell Cancer Therapies

Fineline Cube Jan 5, 2024

German pharmaceutical leader Boehringer Ingelheim (BI) has entered into a new agreement with U.S.-based 3T...

Company Deals

Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances

Fineline Cube Jan 5, 2024

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces...

Company Deals

Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate

Fineline Cube Jan 5, 2024

Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with...

Company Drug

Genrix Bio Seeks China Approval for New Xeligekimab Use in Axial Spondyloarthritis

Fineline Cube Jan 5, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443), a biopharmaceutical company based in China, has submitted...

Policy / Regulatory

Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate

Fineline Cube Jan 5, 2024

The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical...

Company Drug

Akeso Biopharma Submits New Indication Application for Cadonilimab in Gastric Cancer Treatment

Fineline Cube Jan 5, 2024

Akeso Biopharma (HKG: 9926), a leading biopharmaceutical company based in China, has announced the submission...

Company Drug

JW Therapeutics Secures NMPA Review for CAR-T Therapy in Mantle Cell Lymphoma

Fineline Cube Jan 5, 2024

JW Therapeutics (HKG: 2126), a Chinese biopharmaceutical company, has announced that it has submitted an...

Hospital Policy / Regulatory

China’s Ministry of Education Launches Professional Guidelines for Healthcare Talent Training

Fineline Cube Jan 5, 2024

The Ministry of Education (MoE) in China has issued a Notice outlining the “Professional Guidelines...

Company Drug

Jiangsu Hengrui Pharmaceuticals Advances Novel Cancer Therapies with NMPA Clinical Trial Approval

Fineline Cube Jan 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Deals

Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round

Fineline Cube Jan 5, 2024

Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China,...

Posts pagination

1 … 402 403 404 … 648

Recent updates

  • Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer
  • Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer
  • Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease
  • Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
  • Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer

Company Deals

Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer

Company Drug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Company Medical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.